H
Health-Chem Corp. Stock Analysis HCLC
Health-Chem Corp. engages with the developing, manufacturing and marketing of transdermal drug delivery systems. The company is headquartered in New York City, New York and currently employs 206 full-time employees. Transderm owns 98.5% of Hercon Laboratories Corporation, which develops and manufactures controlled release products for the pharmaceutical industry, at Transderm's Pennsylvania facility, to deliver a variety of drugs topically or transdermally. The firm has manufactured over-the-counter pharmaceutical and cosmetic products that are used to clean facial pores. These deep cleansing facial pore strips are designed to remove clogged dirt, oil and blackheads from the nose, chin, forehead and anywhere else on the face that needs deep cleaning. In addition to its nitroglycerin transdermal products, the Company is also developing transdermal products for hormone replacement therapies.
Read More Health-Chem Corp (HCLC) Chart
Key Statistics of Health-Chem Corp (HCLC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
-P/E Ratio (TTM)
-Market Cap
1233.00Avg. Volume
-Dividend Yield
-Financial Metrics & Statements of Health-Chem Corp (HCLC)
FAQ's for Health-Chem Corp (HCLC)
- According to Musaffa’s Shariah screening methodology, Health-Chem Corp (HCLC) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.